Vascular effects of natriuretic peptides in healthy men

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 4, 2004, Pages 263-270

  Komarek, Marius ^a   Bernheim, Alain ^a,b   Schindler, Ruth ^a,b   Steden, Renate ^a   Kiowski, Wolfgang ^a   Brunner La Rocca, Hans Peter ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Down regulation; Guanylate cyclase receptors; Vasodilation

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GUANYLATE CYCLASE; GUANYLATE CYCLASE RECEPTOR; GUANYLATE CYCLASE TYPE A RECEPTOR; GUANYLATE CYCLASE TYPE B RECEPTOR; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INFUSION; FOREARM BLOOD FLOW; FOREARM TISSUE VOLUME; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; ATRIAL NATRIURETIC FACTOR; GUANYLATE CYCLASE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; RECEPTORS, ATRIAL NATRIURETIC FACTOR; VASODILATION;

EID: 12344332902     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900406     Document Type: Article

References (27)

1. Lewicki JA, Protter AA. Physiological studies of the natriuretic peptide family. In Laragh JH and Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. Raven Press, New York; 1029-1053, 1995
2. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 339:321-328, 1998
3. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 130:229-239, 1992
4. Hempel A, Noll T, Bach C, et al. Atrial natriuretic peptide clearance receptor participates in modulating endothelial permeability. Am J Physiol 275:H1818-H1825, 1998
5. Savoie P, de Champlain J, Anand-Srivastava MB. C-type natriuretic peptide and brain natriuretic peptide inhibit adenylyl cyclase activity: Interaction with ANF-R2/ANP-C receptors. FEES Lett 370:6-10, 1995
6. Brunner-La Rocca HP, Woods RL, Kaye DM, et al. Divergent effects of ANP and BNP in acute heart failure: Evidence for a putative BNP-selective receptor? J Hypertens 20:1195-1201, 2002
7. Goy MF, Oliver PM, Purdy KE, et al. Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. Biochem J 358:379-387, 2001
8. Tuinenburg AE, Brundel BJ, Van Gelder IC, et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 10:827-835, 1999
9. Hirooka Y, Takeshita A, Imaizumi T, et al. Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation 82:147-153, 1990
10. Nakamura M, Arakawa N, Yoshida H, et al. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J 135:414-420, 1998
11. Matsumoto T, Wada A, Tsutamoto T, et al. Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure. Am J Physiol 276:H1935-H1942, 1999
12. Bolli P, Muller FB, Linder L, et al. The vasodilator potency of atrial natriuretic peptide in man. Circulation 75:221-228, 1987
13. van der Zander K, Houben AJ, Kroon AA, et al. Effects of brain natriuretic peptide on forearm vasculature: Comparison with atrial natriuretic peptide. Cardiovasc Res 44:595-600, 1999
14. Chen HH, Burnett JCJ. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials. Proc Assoc Am Physicians 111:406-416, 1999
15. Abassi Z, Burnett JC Jr, Grushka E, et al. Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure. Am J Physiol 261:R858-R864, 1991
16. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78:1362-1374, 1986
17. Yoshimura M, Mizuno Y, Harada E, et al. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure. Metabolism 49:1228-1233, 2000
18. Rademaker MT, Charles CJ, Espiner EA, et al. Natriuretic peptide responses to acute and chronic ventricular pacing in sheep. Am J Physiol 270:H594-H602, 1996
19. Grantham JA, Borgeson DD, Burnett JC Jr. BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 272:R1077-R1083, 1997
20. Charles CJ, Espiner EA, Nicholls MG, et al. Bioactivity of natriuretic peptide coinfusions; no evidence for unique effects of BNP in conscious sheep. J Cardiovasc Pharmacol 33:229-326, 1999
21. Nakagawa M, Tanaka I, Mukoyama M, et al. Monoclonal antibody against brain natriuretic peptide and characterization of brain natriuretic peptide-transgenic mice. J Hypertens 19:475-483, 2001
22. John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267:679-681, 1995
23. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 93:1155-1159, 1996
24. Nakamura M, Arakawa N, Yoshida H, et al. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation 90:1210-1214, 1994
25. Schalcher C, Schad K, Brunner-La Rocca HP, et al. Interaction of sildenafil with cAMP-mediated vasodilation in vivo. Hypertension 40:763-767, 2002
26. Woods RL, Jones MJ. Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Am J Physiol 276:R1443-R1452, 1999
27. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared to healthy control subjects. J Am Coll Cardiol 37:1221-1227, 2001